Innate Pharma : Fast track status for IPH4102
>FDA awards fast track status to IPH4102 in Sezary syndrome - Innate Pharma announced this morning that the FDA has granted fast track status for IPH4102 in patients with relapsed or refractory Sezary syndrome (SS) who have received at least two prior treatments. This FDA-approved status is intended to accelerate the development and review of treatments that address important and unmet medical needs. Sezary syndrome is a rare case of cutaneous T-type lymphoma (CTCL) ...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.